Drug Profile
Vutrisiran - Alnylam Pharmaceuticals
Alternative Names: ALN-65492; ALN-TTRsc02; AMVUTTRALatest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Amides; Amino sugars; Drug conjugates; Pyrrolidines; Small interfering RNA
- Mechanism of Action Prealbumin expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Transthyretin-related hereditary amyloidosis
Most Recent Events
- 27 Feb 2024 Registered for Transthyretin-related hereditary amyloidosis in Argentina (SC) (Prior to February 2024)
- 27 Feb 2024 Registered for Transthyretin-related hereditary amyloidosis in Canada (SC) (Prior to February 2024)
- 27 Feb 2024 Registered for Transthyretin-related hereditary amyloidosis in Switzerland (SC) (Prior to February 2024)